Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

17 results
Display

Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy

Chung KH, Ryu JK, Son JH, Lee JW, Jang DK, Lee SH, Kim YT

BACKGROUND/AIMS: Second-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma (PDAC) that progresses following gemcitabine-based treatment has not been established. This study aimed to investigate the efficacy and safety of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Author's Response: Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer

Paik WH, Kim YT

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer

Amin S, Boffetta P, Lucas AL

Survival from pancreatic cancer remains poor. Conventional treatment has resulted in only marginal improvements in survival compared with survival in the previous several decades. Thus, considerable interest has emerged regarding...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Concomitant Statin Use Has a Favorable Effect on Gemcitabine-Erlotinib Combination Chemotherapy for Advanced Pancreatic Cancer

Moon DC, Lee HS, Lee YI, Chung MJ, Park JY, Park SW, Song SY, Chung JB, Bang S

PURPOSE: Erlotinib-gemcitabine combined chemotherapy is considered as the standard treatment for unresectable pancreatic cancer. This study aimed to determine the clinical factors associated with response to this treatment. MATERIALS AND METHODS:...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Systemic Chemotherapy in Advanced Pancreatic Cancer

Lee HS, Park SW

Pancreatic cancer remains one of the most lethal cancers. These patients often have multiple symptoms, and integrated supportive care is critical in helping them remain well for as long as...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Recent Advances in Palliative Chemotherapy for Unresectable Pancreatic Cancer

Ryu JK

Pancreatic adenocarcinoma is one of the fatalist malignancies. A large proportion of patients are diagnosed with unresectable stage pancreatic cancer at the time of presentation. Gemcitabine is a standard chemotherapeutic...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prognostic Factors in Patients with Advanced Pancreatic Cancer Treated with Gemcitabine Chemotherapy: Clinical Characteristics of Long-term Survivors

An SG, Kim DU, Song GA, Jang AL

BACKGROUND/AIMS: Gemcitabine-based chemotherapy has been used as a standard treatment in patients with unresectable pancreatic cancer. However, the clinical outcomes of this regimen are still unsatisfactory in prolonging survival. We...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Chemo-sensitivity Study in Pancreatic Cancer

Lee KH

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Gemcitabine-Induced Hemolytic Uremic Syndrome in Pancreatic Cancer: A Case Report and Review of the Literature

Lee HW, Chung MJ, Kang H, Choi H, Choi YJ, Lee KJ, Lee SW, Han SH, Kim JS, Song SY

  • KMID: 1774536
  • Gut Liver.
  • 2014 Jan;8(1):109-112.
Hemolytic uremic syndrome (HUS) is a rare thrombotic complication characterized by a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS may be caused by several different conditions,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Recent Update of Molecular Targeted Therapy in Pancreatic Cancer

Cho JH

Pancreatic ductal adenocarcinoma is one of the most dreaded malignancies and the 5th leading cause of cancer-related death in Korea. Late diagnosis and unfavorable response to both chemotherapy and radiotherapy...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Expression of Heat Shock Protein 70 Modulates the Chemoresponsiveness of Pancreatic Cancer

Hyun JJ, Lee HS, Keum B, Seo YS, Jeen YT, Chun HJ, Um SH, Kim CD

  • KMID: 1712336
  • Gut Liver.
  • 2013 Nov;7(6):739-746.
BACKGROUND/AIMS: Heat shock protein (HSP) 70 is constitutively overexpressed in pancreatic cancer cells (PCCs) and appears to confer protection against chemotherapeutics. We investigated whether modulating HSP 70 increases chemoresponsiveness to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Second Line Chemotherapy for Pancreatic Cancer

Park JY

Pancreatic cancer is a very lethal cancer. It is the 5th most common cause for cancer related mortality in Korea. Most of patients have unresectable pancreatic cancer, and systemic chemotherapy...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Salvage Chemotherapy after Gemcitabine Failure in Patients with Advanced Pancreatic Cancer: Survival Benefit in Selected Patients

Lee JL, Kim YT

  • KMID: 783035
  • Korean J Gastroenterol.
  • 2008 Jul;52(1):59-63.
No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Chemotherapy for Pancreatic Cancer

Kim YT

  • KMID: 782973
  • Korean J Gastroenterol.
  • 2008 Feb;51(2):111-118.
Chemotherapy is expected to play an important role in the treatment of pancreatic cancer because most of pancreatic cancers are being discovered at locally advanced or metastatic stages and recurrence...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
[6]-Gingerol Induces Cell Cycle Arrest and Cell Death of Mutant p53-expressing Pancreatic Cancer Cells

Park YJ, Wen J, Bang S, Park SW, Song SY

[6]-Gingerol, a major phenolic compound derived from ginger, has anti-bacterial, anti-inflammatory and anti-tumor activities. While several molecular mechanisms have been described to underlie its effects on cells in vitro and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Phase II Study of Combination Chemotherapy with Gemcitabine, 5-fluorouracil, and Cisplatin for Advanced Pancreatic Cancer

Choi SB, Lee HY, Yuh YJ, Kim SR

  • KMID: 772776
  • Korean J Gastroenterol.
  • 2005 May;45(5):348-353.
BACKGROUND/AIMS: Gemcitabine has been the standard regimen for advanced pancreatic cancer, but the effect on the response rate and survival is still disappointing, leading to many trials of combination...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Gemcitabine Therapy in Patients with Advanced Pancreatic Cancer

Min YJ, Joo KR, Park NH, Yun TK, Nah YW, Nam CW, Park JH

  • KMID: 759621
  • Korean J Intern Med.
  • 2002 Dec;17(4):259-262.
BACKGROUND: Advanced, unresectable pancreatic cancer is an extremely aggressive disease. The 5-year survival rate for pancreatic cancer is only less than 5%. Current therapeutic options for patients with locally...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr